## Wei-Ping Zhou

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5254289/publications.pdf

Version: 2024-02-01

147726 133188 6,302 59 31 59 citations h-index g-index papers 61 61 61 9005 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Development of preoperative prognostic models including radiological features for survival of singular nodular HCC patients. Hepatobiliary and Pancreatic Diseases International, 2022, , .	0.6	4
2	HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBVâ€Related HCC Through Reciprocal Regulation With Insulinâ€Like Growth Factor 2 mRNAâ€Binding Protein 3. Hepatology, 2021, 74, 1480-1495.	3.6	44
3	Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis. Bioengineered, 2021, , .	1.4	1
4	Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3†cm †A retrospective cohort study. American Journal of Surgery, 2020, 219, 717-725.	0.9	12
5	A Noncoding Regulatory RNAs Network Driven by Circ DYL Acts Specifically in the Early Stages Hepatocellular Carcinoma. Hepatology, 2020, 71, 130-147.	3.6	165
6	Plasma circular RNA panel to diagnose hepatitis B virusâ€related hepatocellular carcinoma: A largeâ€scale, multicenter study. International Journal of Cancer, 2020, 146, 1754-1763.	2.3	83
7	Trans-acting non-synonymous variant of FOXA1 predisposes to hepatocellular carcinoma through modulating FOXA1-ERα transcriptional program and may have undergone natural selection. Carcinogenesis, 2020, 41, 146-158.	1.3	3
8	miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy. Gut, 2020, 69, 1309-1321.	6.1	78
9	Survival advantage associated with metformin usage in hepatocellular carcinoma patients with diabetes mellitus receiving radical resection: a propensity score matching analysis. European Journal of Gastroenterology and Hepatology, 2020, 32, 1030-1035.	0.8	9
10	Nomograms to predict the longâ€time prognosis in patients with alphaâ€fetoprotein negative hepatocellular carcinoma following radical resection. Cancer Medicine, 2020, 9, 2791-2802.	1.3	19
11	miR-515–5p suppresses HCC migration and invasion via targeting IL6/JAK/STAT3 pathway. Surgical Oncology, 2020, 34, 113-120.	0.8	36
12	MicroRNAâ€197â€3p acts as a prognostic marker and inhibits cell invasion in hepatocellular carcinoma. Oncology Letters, 2019, 17, 2317-2327.	0.8	38
13	Tropomodulin 3 modulates EGFRâ€Pl3Kâ€AKT signaling to drive hepatocellular carcinoma metastasis. Molecular Carcinogenesis, 2019, 58, 1897-1907.	1.3	27
14	Multiple hepatocellular carcinomas: liver resection or transcatheter arterial chemoembolization?. Hepatobiliary Surgery and Nutrition, 2019, 8, 519-521.	0.7	3
15	Temporary Ischemia Time Before Snap Freezing Is Important for Maintaining High-Integrity RNA in Hepatocellular Carcinoma Tissues. Biopreservation and Biobanking, 2019, 17, 425-432.	0.5	7
16	Co-Upregulation of 14-3-3ζ and P-Akt is Associated with Oncogenesis and Recurrence of Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2018, 45, 1097-1107.	1.1	12
17	IL â€17A promotes the invasion–metastasis cascade via the AKT pathway in hepatocellular carcinoma. Molecular Oncology, 2018, 12, 936-952.	2.1	19
18	Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. Journal of Hepatology, 2018, 68, 1214-1227.	1.8	574

#	Article	IF	Citations
19	Impact of Preoperative Hepatitis B Virus Levels on Prognosis After Primary and Repeat Hepatectomies for Hepatocellular Carcinoma Patients—a Retrospective Study. Journal of Gastrointestinal Surgery, 2018, 22, 872-883.	0.9	5
20	Dual regulation of HMGB1 by combined JNK1/2–ATF2 axis with miRâ€200 family in nonalcoholic steatohepatitis in mice. FASEB Journal, 2018, 32, 2722-2734.	0.2	24
21	Hepatitis B virus X protein promotes the stem-like properties of OV6+ cancer cells in hepatocellular carcinoma. Cell Death and Disease, 2018, 8, e2560-e2560.	2.7	43
22	Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine. Journal of Integrative Medicine, 2018, 16, 236-248.	1.4	61
23	Overactivated neddylation pathway in human hepatocellular carcinoma. Cancer Medicine, 2018, 7, 3363-3372.	1.3	35
24	Early enforced mobilization after liver resection: A prospective randomized controlled trial. International Journal of Surgery, 2018, 54, 254-258.	1.1	40
25	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer, 2018, 7, 235-260.	4.2	426
26	Lamp2 inhibits epithelial-mesenchymal transition by suppressing Snail expression in HCC. Oncotarget, 2018, 9, 30240-30252.	0.8	3
27	Hepatocellular carcinoma with inferior vena caval and right atrial tumor thrombi and massive pulmonary artery embolism: A case report. Molecular and Clinical Oncology, 2017, 6, 111-114.	0.4	10
28	Zinc finger protein Xâ€linked promotes expansion of EpCAM <sup>+</sup> cancer stemâ€like cells in hepatocellular carcinoma. Molecular Oncology, 2017, 11, 455-469.	2.1	21
29	The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1. Nature Cell Biology, 2017, 19, 820-832.	4.6	245
30	METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N 6â€methyladenosineâ€dependent primary MicroRNA processing. Hepatology, 2017, 65, 529-543.	3.6	685
31	Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients. Oncotarget, 2017, 8, 28621-28627.	0.8	27
32	CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma. Oncotarget, 2017, 8, 18872-18884.	0.8	42
33	Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma. Hepatology, 2016, 63, 850-863.	3.6	101
34	Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology, 2016, 63, 499-511.	3.6	332
35	TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling. Scientific Reports, 2016, 6, 37070.	1.6	61
36	Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy. Surgical Oncology, 2016, 25, 171-177.	0.8	10

#	Article	IF	CITATIONS
37	Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nature Communications, 2016, 7, 12992.	5.8	228
38	Serum miRNAs as predictive and preventive biomarker for pre-clinical hepatocellular carcinoma. Cancer Letters, 2016, 373, 234-240.	3.2	43
39	Long noncoding RNA, the methylation of genomic elements and their emerging crosstalk in hepatocellular carcinoma. Cancer Letters, 2016, 379, 239-244.	3.2	36
40	Overexpression of CHKA contributes to tumor progression and metastasis and predicts poor prognosis in colorectal carcinoma. Oncotarget, 2016, 7, 66660-66678.	0.8	23
41	elF5B increases ASAP1 expression to promote HCC proliferation and invasion. Oncotarget, 2016, 7, 62327-62339.	0.8	24
42	Paraoxonase 3 inhibits cell proliferation and serves as a prognostic predictor in hepatocellular carcinoma. Oncotarget, 2016, 7, 70045-70057.	0.8	13
43	Aldolase B inhibits metastasis through Ten–Eleven Translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma. Molecular Cancer, 2015, 14, 170.	7.9	64
44	Antiviral Therapy Improves Postoperative Survival in Patients With Hepatocellular Carcinoma. Annals of Surgery, 2015, 261, 56-66.	2.1	178
45	Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4. Gut, 2015, 64, 156-167.	6.1	115
46	Pioglitazone, a PPAR $\hat{I}^3$ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling. Molecular Carcinogenesis, 2015, 54, 1584-1595.	1.3	44
47	Selective Hepatic Vascular Exclusion versus Pringle Maneuver in Partial Hepatectomy for Liver Hemangioma Compressing or Involving the Major Hepatic Veins. American Surgeon, 2014, 80, 236-240.	0.4	10
48	Prediction of Hepatocellular Carcinoma Recurrence in Patients With Low Hepatitis B Virus DNA Levels and High Preoperative Hepatitis B Surface Antigen Levels. JAMA Surgery, 2014, 149, 519.	2.2	43
49	Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: A RCT. Journal of Hepatology, 2014, 61, 82-88.	1.8	271
50	A Long Noncoding RNA Activated by TGF- $\hat{l}^2$ Promotes the Invasion-Metastasis Cascade in Hepatocellular Carcinoma. Cancer Cell, 2014, 25, 666-681.	7.7	1,392
51	Surgery for pregnancy-associated primary hepatocellular carcinoma: Report of four cases. International Journal of Surgery Case Reports, 2014, 5, 882-885.	0.2	9
52	The histone acetyltransferase hMOF suppresses hepatocellular carcinoma growth. Biochemical and Biophysical Research Communications, 2014, 452, 575-580.	1.0	37
53	Preoperative Hepatitis B Virus DNA Level is a Risk Factor for Postoperative Liver Failure in Patients Who Underwent Partial Hepatectomy for Hepatitis Bâ€Related Hepatocellular Carcinoma. World Journal of Surgery, 2014, 38, 2370-2376.	0.8	11
54	Antisense long non-coding RNA PCNA-AS1 promotes tumor growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma. Cancer Letters, 2014, 349, 87-94.	3.2	95

#	Article	IF	CITATIONS
55	Opposite regulation of hepatic breast cancer resistance protein in type 1 and 2 diabetes mellitus. European Journal of Pharmacology, 2014, 724, 185-192.	1.7	11
56	Rpb3 promotes hepatocellular carcinoma through its N-terminus. Oncotarget, 2014, 5, 9256-9268.	0.8	8
57	MUC15 Inhibits Dimerization of EGFR and PI3K–AKT Signaling and Is Associated With Aggressive Hepatocellular Carcinomas in Patients. Gastroenterology, 2013, 145, 1436-1448.e12.	0.6	111
58	Early Viral Suppression Predicts Good Postoperative Survivals in Patients with Hepatocellular Carcinoma with a High Baseline HBV-DNA Load. Annals of Surgical Oncology, 2013, 20, 1482-1490.	0.7	35
59	A Prospective, Randomized, Controlled Trial of Preoperative Transarterial Chemoembolization for Resectable Large Hepatocellular Carcinoma. Annals of Surgery, 2009, 249, 195-202.	2.1	177